STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir has today together with its partner Tibotec presented data from the ongoing phase IIa trial with TMC435350. These data were presented at the 59th Annual Meeting of the American Association for Study of Liver Diseases (AASLD) meeting in San Francisco held between October 31 - November 4.
